Febuxostat Compared with Allopurinol in Patients With Hyperuricemia and Gout
By J. Stockman. 2007
1,203 citations recorded by the source corpus.
Subfields: Nephrology, Public Health, Environmental and Occupational Health, Surgery
View Paper: https://www.semanticscholar.org/paper/57d9c3c9a35031434d19af8562fa25b67e871022
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Nephrology
In Surgery
Citations in the corpus
- Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout (2009, background): “; the treatment is often insufficient, with only 21% of gout patients who receive the most common urate-lowering treatment, reaching optimal serum urate levels in clinical trials (12, 13).”
- Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol (2006, background): “From the small number of current examples of the development of novel XO inhibitor compounds that have entered a clinical phase (Becker et al., 2004, 2005; Fukunari et al., 2004; Komoriya et al., 2004; Yamada et al., 2004; Hashimoto et al., 2005; Mayer et al., 2005; Takano et al., 2005), it appears…”
- 2012 American College of Rheumatology Guidelines for Management of Gout Part II: Therapy and Anti-inflammatory Prophylaxis of Acute Gouty Arthritis (2012, background): “Specifically, the TFP voted to continue the prophylaxis for the greater of: 1) 6 months’ duration (evidence A) (51,53,54), 2) 3 months after achieving the target serum urate level for the patient without tophi detected on physical examination (evidence B), or 3) 6 months after achieving the target s”
- Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study (2008, background): “Errors are frequently made in allopurinol use (46), and only 21% of patients randomized to allopurinol in a clinical trial achieved optimal UA levels (44).”